- Conditions
- Leukemia, Renal Toxicity
- Interventions
- methotrexate, medical chart review, assessment of therapy complications
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 41
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hyperkalemia, Chronic Kidney Disease, Kidney Dysfunction
- Interventions
- Zirconium silicate (ZS), Placebo
- Drug
- Lead sponsor
- ZS Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- Tempe, Arizona • Costa Mesa, California • Edgewater, Florida + 6 more
- Conditions
- Uremic Pruritus
- Interventions
- CR845 0.5 mcg/kg, Placebo
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 57
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
- Conditions
- Gastrointestinal Cancer
- Interventions
- Oxaliplatin (SR96669)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- High Blood Pressure, Liver Transplant, Renal Function Abnormal
- Interventions
- Amlodipine Besylate, Chlorthalidone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- exatecan mesylate
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Fort Sam Houston, Texas • San Antonio, Texas
- Conditions
- Hot Weather; Adverse Effect, Kidney Dysfunction, Kidney Injury, Hyperthermia, Dehydration
- Interventions
- Fluid replacement, No fluid replacement
- Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- Heart Failure, Kidney Dysfunction
- Interventions
- Furosemide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2,050 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Uremic Pruritus
- Interventions
- CR845 0.5 mcg/kg
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 33
- States / cities
- Escondido, California • Riverside, California • San Diego, California + 26 more
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Sacramento, California • South Pasadena, California + 13 more
- Conditions
- Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
- Interventions
- measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
- Device
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- Lenalidomide, Dexamethasone, Anticoagulants
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
- Conditions
- Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma
- Interventions
- Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2027
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • Duarte, California • Lancaster, California + 21 more
- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Northridge, California • Miami, Florida • Miami Lakes, Florida + 5 more
- Conditions
- Kidney Graft Dysfunction
- Interventions
- Cyclosporins/Tacrolimus, Sirolimus
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Neoplasms
- Interventions
- ABT-888, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 110 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Primary Hepatocellular Carcinoma, Adult Subependymoma, Advanced Adult Primary Liver Cancer, Advanced Malignant Mesothelioma, Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Malignant Mesothelioma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage II Esophageal Cancer, Stage II Pancreatic Cancer, Stage III Esophageal Cancer, Stage III Pancreatic Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- erlotinib hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Complication of Transplanted Liver
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 83
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Surprise, Arizona + 76 more
- Conditions
- Delayed Graft Function
- Interventions
- ANG-3777, Placebo
- Drug · Other
- Lead sponsor
- Angion Biomedica Corp
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
- Conditions
- Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
- Interventions
- Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule, Thrice-Weekly Hemodialysis
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Long Beach, California • West Los Angeles, California • West Haven, Connecticut + 5 more
- Conditions
- Hot Weather; Adverse Effect, Kidney Dysfunction, Kidney Injury, Hyperthermia, Dehydration
- Interventions
- 23.0°C WBGT - Fixed Work Rate, 25.5°C WBGT - Fixed Work Rate, 27.5°C WBGT - Fixed Work Rate, 28.5°C WBGT - Fixed Work Rate, 35.5°C WBGT - Fixed Work Rate, 26.0°C WBGT - Fixed work-to-rest ratio, 30.5°C WBGT - Fixed work-to-rest ratio, 30.5°C WBGT - Fixed work-to-rest ratio (high intensity)
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana